Soluble Urokinase‐Type Plasminogen Activator Receptor, Changes of 24‐Hour Blood Pressure, and Progression of Chronic Kidney Disease

Soluble Urokinase‐Type Plasminogen Activator Receptor, Changes of 24‐Hour Blood Pressure, and Progression of Chronic Kidney Disease

Background Soluble urokinase‐type plasminogen activator receptor (suPAR) is associated with cardiovascular risks and poor renal outcomes. However, whether elevated suPAR levels are associated with 24‐hour blood pressure patterns or kidney disease progression in patients with chronic kidney disease (...

Full description

Bibliographic Details
Main Authors:	Jong Hyun Jhee, Bo Young Nam, Chan Joo Lee, Jung Tak Park, Seung Hyeok Han, Shin‐Wook Kang, Sungha Park, Tae‐Hyun Yoo
Format:	Article
Language:	English
Published:	Wiley 2021-01-01
Series:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:	chronic kidney disease dipping pattern progression of kidney disease soluble urokinase‐type plasminogen activator receptor
Online Access:	https://www.ahajournals.org/doi/10.1161/JAHA.120.017225

Similar Items

Soluble urokinase-type plasminogen activator receptor as a biomarker for focal segmental glomerulosclerosis; a retrospective analysis
by: Miguel Verdelho, et al.
Published: (2018-07-01)

Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin′s Lymphoma
by: Shirin Kouhpayeh, et al.
Published: (2017-01-01)

Value of soluble Urokinase plasminogen activator receptor over age as a biomarker of impaired myocardial relaxation
by: Koh, Angela S., et al.
Published: (2018)

Clinical value of soluble urokinase-type plasminogen activator receptor in predicting sepsis-associated acute kidney injury
by: Wenwen Zhang, et al.
Published: (2024-12-01)

Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19
by: Shengyuan Luo, et al.
Published: (2022-09-01)

The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia
by: Nergiz Erkut, et al.
Published: (2016-05-01)

Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High‐Sensitivity C‐Reactive Protein
by: Salim S. Hayek, et al.
Published: (2018-05-01)

Soluble urokinase plasminogen activator receptor and its complicated role in hemodialysis (HD) patients with Covid-19 infection
by: Ioannis Griveas, et al.
Published: (2021-07-01)

Predictive value of soluble urokinase-type plasminogen activator receptor in patients with severe acute pancreatitis
by: LI Yang, et al.
Published: (2022-02-01)

Association between serum soluble urokinase-type plasminogen activator receptor and atrial fibrillation
by: Noboru Ichihara, et al.
Published: (2017-10-01)

Value of soluble Urokinase plasminogen activator receptor over age as a biomarker of impaired myocardial relaxation
by: Angela S. Koh, et al.
Published: (2017-11-01)

The Predictive Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention
by: Qin Y, et al.
Published: (2021-10-01)

Can serum soluble urokinase plasminogen activator receptor be an effective biomarker in comparing the inflammatory response between laparoscopic and open appendectomy?
by: Basak Erginel, et al.
Published: (2023-06-01)

Local Production of Soluble Urokinase Plasminogen Activator Receptor and Plasminogen Activator Inhibitor‐1 in the Coronary Circulation Is Associated With Coronary Endothelial Dysfunction in Humans
by: Michel T. Corban, et al.
Published: (2018-08-01)

Association between the Serum Soluble Urokinase Plasminogen Activator Receptor and Peripheral Arterial Stiffness According to the Cardio-Ankle Vascular Index in Patients Undergoing Kidney Transplantation
by: Hsiao-Hui Yang, et al.
Published: (2024-06-01)

Soluble urokinase-type plasminogen activator receptor as a biomarker of treatment response in childhood tuberculosis
by: Ery Olivianto, et al.
Published: (2019-01-01)

Febrile phase soluble urokinase plasminogen activator receptor and olfactomedin 4 as prognostic biomarkers for severe dengue in adults
by: Teo, Andrew, et al.
Published: (2024)

Proteomics-Based Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated With Incident Heart Failure Risk
by: Adithya K. Yadalam, MD, MSc, et al.
Published: (2025-01-01)

Effect of remission induction therapy on the level of soluble urokinase plasminogen activator receptor in acute myeloid leukemia
by: Eman Qassim Ahmed, et al.
Published: (2020-01-01)

Cardio‐Renal Biomarker Soluble Urokinase‐Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Patients With Coronary Artery Disease Independent of Troponin, C‐Reactive Protein, and Renal Function
by: Julius Nikorowitsch, et al.
Published: (2020-04-01)

Serum levels of soluble urokinase plasminogen activator receptor in juvenile idiopathic arthritis: a single-center Swedish case-control study
by: Per Lewander, et al.
Published: (2023-05-01)

The accuracy of soluble urokinase-type plasminogen activator receptor for the diagnosis of neonatal sepsis: a meta-analysis
by: Jinjin Ma, et al.
Published: (2023-04-01)

Specific inhibitors of urokinase plasminogen activator for treatment of cancers; In silico approach
by: Benjamin Talbot, et al.
Published: (2020-05-01)

Study the effect of urokinase-type plasminogen activator (UPA) and some biochemical parameters in Iraqi hemodialysis patients with type 2 diabetes
by: Fatima Ali Essa Al-Sudani, et al.
Published: (2024-01-01)

Serum levels of urokinase-type plasminogen activator in healthy dogs and oncologic canine patients
by: Sofia C. Ramos, et al.
Published: (2017-08-01)

Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors
by: Lampelj Maja, et al.
Published: (2015-12-01)

Urokinase-type plasminogen activator is a modulator of synaptic plasticity in the central nervous system: implications for neurorepair in the ischemic brain
by: Manuel Yepes
Published: (2020-01-01)

Monitoring of chemotherapy successfulness of Platina/Taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II
by: Dženita Ljuca, et al.
Published: (2007-05-01)

The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine
by: Jan Simon Scharrenberg, et al.
Published: (2019-11-01)

Predictive value of plasma soluble urokinase-type plasminogen activator receptor for post-severe traumatic multiple organ dysfunction syndrome
by: ZHAO Yinjie, et al.
Published: (2021-04-01)

Soluble urokinase-type plasminogen activator receptor as a measure of treatment response in acute exacerbation of COPD
by: Gehan Hassan AboEl-Magd, et al.

Concentrations of plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in induced sputum of asthma patients after allergen challenge
by: Krzysztof Kowal,, et al.
Published: (2010-04-01)

Diagnostic and Prognostic Values of Serum C-reactive Protein, Procalcitonin, Soluble Urokinase Plasminogen Activator Receptor, and Neopterin Levels in Hospitalized Patients in the Intensive Care Unit with Ventilator-associated Pneumonia
by: Reyhan ÖZTÜRK, et al.
Published: (2021-12-01)

The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets
by: Ashna A. Kumar, et al.
Published: (2022-01-01)

The effect of amiloride in decreasing albuminuria in patients with diabetic kidney diseases: a prospective, crossover, open-label study
by: Ruizhao Li, et al.
Published: (2021-01-01)

Soluble Urokinase Plasminogen Activator Receptor Is Associated With Subclinical Myocardial Impairment by Speckle Tracking Echocardiography in Lung Cancer Patients
by: Ahmad S. Manshad, et al.
Published: (2022-01-01)

QSAR modelling to predict structural features of certain sulfonamide as Urokinase-type Plasminogen Activator inhibitors
by: Rahul D. Jawarkar, et al.
Published: (2024-06-01)

Inhibitory effects of wogonin on invasion by human oral cancer cells by decreasing the activity of matrix metalloproteinases and urokinase-plasminogen activator
by: Yung-Chuan Ho, et al.
Published: (2014-06-01)

Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19
by: Tetiana Yatsenko, et al.
Published: (2024-01-01)

Corrigendum: Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19
by: Tetiana Yatsenko, et al.
Published: (2024-03-01)